Investigational Drug Information for Radotinib
✉ Email this page to a colleague
What is the drug development status for Radotinib?
Radotinib is an investigational drug.
There have been 7 clinical trials for Radotinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 28th 2018.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and Leukemia. The leading clinical trial sponsors are Il-Yang Pharm. Co., Ltd., Asan Medical Center, and Ulsan University Hospital.
There are sixty-one US patents protecting this investigational drug and zero international patents.
Summary for Radotinib
| US Patents | 61 |
| International Patents | 1,051 |
| US Patent Applications | 238 |
| WIPO Patent Applications | 339 |
| Japanese Patent Applications | 57 |
| Clinical Trial Progress | Phase 3 (2018-12-28) |
| Vendors | 48 |
Recent Clinical Trials for Radotinib
| Title | Sponsor | Phase |
|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Il-Yang Pharm. Co., Ltd. | Phase 2 |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | Il-Yang Pharm. Co., Ltd. | Phase 3 |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | Il-Yang Pharm. Co., Ltd. | Phase 3 |
Clinical Trial Summary for Radotinib
Top disease conditions for Radotinib
Top clinical trial sponsors for Radotinib
US Patents for Radotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Radotinib | ⤷ Sign Up | Heteroaryl compounds as IRAK inhibitors and uses thereof | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| Radotinib | ⤷ Sign Up | Heteroaryl compounds as BTK inhibitors and uses thereof | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| Radotinib | ⤷ Sign Up | 3-substituted cyclopentylamine derivatives | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| Radotinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Radotinib | ⤷ Sign Up | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl- )methanones | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | ⤷ Sign Up |
| Radotinib | ⤷ Sign Up | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Radotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Radotinib | Argentina | AR103138 | 2034-11-20 | ⤷ Sign Up |
| Radotinib | Australia | AU2015349899 | 2034-11-20 | ⤷ Sign Up |
| Radotinib | Brazil | BR112017009800 | 2034-11-20 | ⤷ Sign Up |
| Radotinib | Canada | CA2964982 | 2034-11-20 | ⤷ Sign Up |
| Radotinib | China | CN107108561 | 2034-11-20 | ⤷ Sign Up |
| Radotinib | Denmark | DK3221306 | 2034-11-20 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
